Latest GeneDx News & Updates

See the latest news and media coverage for GeneDx. We track all announcements, press releases, and industry mentions in real time, all in one place.

GeneDx

Rare disease genetic testing and genomic diagnostics company

genedx.com

Headquarters: Stamford, United States
Company type: Public company
Number of employees: 1,200–5,000
Industry: Biotechnology & Medical Research

Last updated October 24

Latest news about GeneDx

In short: GeneDx reported higher Q2 revenue, reaffirmed 2026 guidance, and expanded genomic testing coverage.

Company announcements

August 3 GeneDx

GeneDx reports Q2 2026 earnings showing strong revenue growth

Revenue reached $114.4 million with a 32% year-over-year volume increase. The company announced guidance for full-year and third-quarter results alongside a Blackstone investment.

May 4 GeneDx

GeneDx reports Q1 2026 financial results and updates guidance

Revenue reached $102.3 million with 34% volume growth but full-year revenue guidance was lowered to $475-490 million due to mix shifts.

February 23 GeneDx

GeneDx reported Q4 and FY2025 results, reaffirmed 2026 guidance

Revenue grew 27% to $121M, exome and genome test revenue up 32%, adjusted net income $4.4M.

February 1 GeneDx

GeneDx reports strong Q4 and full year financial results

Revenue reached $121.0 million in Q4 and $427.5 million for the full year, with a new FY2026 revenue guidance of $540 to $555 million.

Media coverage

October 24 AInvest

Why Is WGS Stock Rising Today? GeneDx Posts Q2 Earnings Beat and Return to Profitability

GeneDx reported Q2 revenue of $114.4M, exceeding estimates, and returned to adjusted profitability, driving a 10.42% ...

August 2 Woonsocket Call

GeneDx Reports Second Quarter 2026 Financial Results

GeneDx Reports Second Quarter 2026 Financial Results...

July 31 MSN

GeneDx Holdings Corp. (WGS) Q2 earnings and revenues surpass estimates

GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share...

June 4 Simply Wall St

GeneDx Holdings (WGS) Is Up 12.2% After Deep Guidance Cut And Fabric Impairment - What's Changed - Simply Wall St News

GeneDx Holdings Corp. recently reported a major first-quarter 2026 earnings miss, a much larger net loss, reduced full-year revenue guidance, and a sizable impairment tied...

Never miss news about GeneDx

Track GeneDx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

GeneDx competitors & trending companies

Browse news for competitors to GeneDx and other trending companies.